Loading
Life sciences · Journal article
Journal of Gynecologic Oncology · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Objective: To characterize real-world implementation of novel therapies in gynecological oncology in Japan and identify actionable gaps through a nationwide survey.Methods: A cross-sectional questionnaire was distributed to Japan Society of Obstetrics and Gynecology-affiliated institutions.The items covered institution characteristics; use of poly (ADP-ribose) polymerase (PARP) inhibitors, immune checkpoint inhibitors (ICIs), kinase inhibitors, and antibody-based agents; local adverse event (AE) manuals; availability of expert panels and immune-related adverse event (irAE) teams; and perceptions of educational sufficiency.Results: Valid responses were obtained from 245 institutions, spanning universities, cancer centers, and general hospitals.Most institutions reported the routine use of PARP inhibitors, ICIs, kinase inhibitors, and antibody drugs.However, only 40.4% of institutions had an in-hospital irAE management team, 57.1% had an AE/irAE manual, and 31.0%and 12.2% considered prior educational opportunities sufficient for physicians and nurses/other medical staff, respectively.High-volume institutions and academic centers were significantly more likely to have medical oncology support, expert-panel access, irAE teams, manuals,